https://t.co/YKGVY4WzGc https://t.co/umvvm1pwwt CATT trial. Patients who responded to VEGF tend to stay responsive. Interesting to see the crossover patients. The subgroup I am looking at is the patients who responded well in Y1 -> switched to PRN injec…
Nice idea but would need to know more to judge whether this would be legal under current framework or require new regulatory approach. https://t.co/cIo4R1vHvn
@stephensenn @JohnTuckerPhD can get reasonable estimates of whether the difference is greater than gains from £84M more spend on health care https://t.co/d8OW5GCJ41
Both effective for AMD main cause of blindness, bevcuzimab 1/20th price ranibizumab but doctors told not to use it. https://t.co/H3BFsopi8y